Final results of a phase I study of Y-90-ibritumomab-tiuxetan (Y-90-IT) in children with recurrent/refractory CD20 positive lymphoma: A COG phase I consortium study
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS（2006）
关键词
positive lymphoma,ibritumomab-tiuxetan
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要